Enhancing Global Access to Disease-Modifying Therapies
By transitioning from monoclonal antibody therapy to active vaccination, we significantly lower the costs of these disease-modifying therapies by at least an order of magnitude. This reduction enables us to substantially increase the number of potential patients, including those in more financially constrained circumstances.
DeepVax: Targeting cancer with vaccines
DeepVax is a a research-based biomedical company founded in July 2018 and headquartered in Zurich, Switzerland.
DeepVax is primarily engaged in the discovery, development, manufacturing and marketing of innovative therapies for the treatment of cancer. DeepVax focuses on translational oncology research; more specifically on innovative personalized therapeutic cancer vaccines as well as immune-stimulators and immune-enhancer therapeutic cancer products.